Cisplatin Neurotoxicity Presenting as Reversible Posterior Leukoencephalopathy Syndrome
AJNR 19:415-417, 5911998., Ito,Y.,et al, 1998
Brain Infarction Following 5-Fluorouracil and Cisplatin Therapy
Neurol 52:899-901, Amrani,M.E.,et al, 1998
Regional Subacute Cranial Neuropathies Following Internal Carotid Cisplatin Infusion
Neurol 47:1088-1090, Alderson,L.M.,et al, 1996
Peripheral Neuropathy from Taxol and Cisplatin Combination Chemotherapy:Clinical and Electrophysiological Studies
Ann Neurol 35:304-311, Chaudhry,V.,et al, 1994
Intra-arterial Cisplatin-Associated Optic and Otic Toxicity
Arch Neurol 49:83-86, Maiese,K.,et al, 1992
Cisplatin Neurotoxicity
NEJM 323:64-65, Lindeman,G.,et al, 1990
Autonomic Neuropathy After Treatmant with Cisplatin, Vinblastine, and Bleomycin for Germ Cell Cancer
BMJ 300:511-512, Hansen,S.W., 1990
Prevention of Cisplatin Neurotoxicity with an ACTH (4-9) Analogue in Patients with Ovarian Cancer
NEJM 322:89-94, 126-1271990., Gerritsen Van Der Hoop,R.,et al, 1990
Decreased Phenytoin Levels in Patients Receiving Chemotherapy
Am J Med 87:505-510, Grossman,S.A., 1989
Unusual Presentation of Cis-Platinum Neuropathy
Neurol 38:488-490, Mollman,J.E.,et al, 1988
Visual System Toxicity Following Intra-arterial Chemotherapy
Neurol 38:284-289, Kupersmith,M.J.,et al, 1988
Regional Nerve Injury After Intra-Arterial Chemotherapy
Neurol 37:834-837, Castellanos,A.M.,et al, 1987
Cisplatin Neuropathy with Lhermitte's Sign
JNNP 49:96-99, Dewar,J.,et al, 1986
Peripheral Sensory Neuropathy & Cisplatin Chemotherapy
Neurol 34:934-938, Roelofs,R.I.,et al, 1984
Cisplatin Neuropathy
Cancer 54:1269-1275, Thompson,S.W.,et al, 1984
Neurotoxic Effects of Cisplatin Therapy
Arch Neurol 39:719-720, Walsh,T.J.,et al, 1982
Cis-diamminedichloroplatinum (II) , A New Anticancer Drug
Ann Int Med 86:803-812, Rozencweig,M.,et al, 1977
Frequency and Diagnostic Implications of Paramagnetic Rim Lesions in People Presenting for Diagnosis to a Multiple Sclerosis Clinic
Neurol 105:e213912, Remner,B.,et al, 2025
Diagnosis of Multiple Sclerosis: 2024 Revisions of the McDonald Criteria
Lancet Neurol 24:850-865, Montalban,X.,et al, 2025
The Optic Nerve Should Graduate to Be the Fifth Lesion Site for the Diagnosis of Multiple Sclerosis
Neurol 102:e207919, Galetta,S. & Brownlee, W., 2024
Management of Possible Multiple Sclerosis
NEJM 388:2195-2190, , 2023
Association of Very Early treatment Initiation with the Risk of Long-Term Disability in Patients with a First Demyelinating Event
Neurol 101:e1280-e1292, 549, Cobo-Calvo,A.,et al, 2023
Inclusion of Optic Nerve Involvement in Dissemination in Space Criteria for Multiple Sclerosis
Neurol 91:e1130-e1134,545, Brownlee, W.J.,et al, 2018
Application of the 2017 Revised McDonald Criteria for Multiple Sclerosis to Patients with a Typical Clinically Isolated Syndrome
JAMA Neurol 75:1392-1398, Van Der Vuurst De Vries, R.M.,et al, 2018
Effects of Bacille Calmette-Guerin after the first Demyelinating event in the CNS
Neurol 82:41-48, Ristori, G.,et al, 2014
Spinal Cord Lesions in Patients with Clinically Isolated Syndrome
Neurol 80:69-75, Sombekke, M.,et al, 2013
Location of Brain Lesions Predicts Conversion of Clinically Isolated Syndromes to Multiple Sclerosis
Neurol 80:234-241, Giorgio, A.,et al, 2013
Association Between Immediate Initiation of Intramuscular Interferon Beta-1a at the Time of a Clinically Isolated Syndrome and Long-term Outcomes
Arch Neurol 69:183-190, Kinkel,R.P.,et al, 2012
Monosymptomatic Clinically Isolated Syndrome with Sudden Sensorineural Hearing Loss
The Neurologist 18:302-305, Anagnostouli, M.C.,et al, 2012
MRI Only Conversion to Multiple Sclerosis Following a Clinically Isolated Syndrome
JNNP 82:176-179, Chard,D.T.,et al, 2011
Optic Neuritis: Prognosis and Treatment
UpToDate, Jan, Osborne, B.,et al, 2011
A Comparison of MRI Criteria for Diagnosing Pediatric ADEM and MS
Neurol 74:1412-1415, 1404, Ketelslegers,I.A., et al, 2010
Brainstem Lesion in Clinically Isolated Syndromes
Neurol 75:1933-1938, Tintore,M.,et al, 2010
Relapse Management in Multiple Sclerosis
The Neurologist 15:1-5, Thrower,B.W., 2009
Early MRI in Optic Neuritis: The Risk for Disability
Neurol 72:542-550, Swanton,.K.,et al, 2009
Incidental MRI Anomalies Suggestive of Multiple Sclerosis: The Radiologically Isolated Syndrome
Neurol 72:800-805,780, Okuda,D.T.,et al, 2009
A Single, Early Magnetic Resonance Imaging Study in the Diagnosis of Multiple Sclerosis
Arch Neurol 66:587-592, Rovira,A.,et al, 2009
Association Between Clinical Conversion to Multiple Sclerosis in Radiologically Isolated Syndrome and Magnetic Resonance Imaging, Cerebrospinal Fluid, and Visual Evoked Potential: Follow-Up of 70 Patients
Arch Neurol 66:841-846, Lebrun,C.,et al, 2009
Real-Life Impact of Early Interferon� Therapy in Relapsing Multiple Sclerosis
Ann Neurol 66:513-520, Trojano,M.,et al, 2009
Magnetic Resonance Imaging Predictors of Conversion to Multiple Sclerosis in the BENEFIT Study
Arch Neurol 66:1345-1352, Moraal,B.,et al, 2009
Effect of Glatiramer Acetate on Conversion to Clinically Definite Multiple Sclerosis in Patients with Clinically Isolated Syndrome (PreCISe study): A Randomised, Double-Blind, Placebo-Controlled Trial
Lancet 374:1503-1511, 1475, Martinelli,G.,et al, 2009
Unexpected Multiple Sclerosis: Follow-Up of 30 Patients With Magnetic Resonance Imaging and Clinical Conversion Profile
JNNP 79:195-198,112, Lebrun,C.,et al, 2008
Do Oligoclonal Bands Add Information to MRI in First Attacks of Multiple Sclerosis?
Neurol 70:1079-1083,1059, Tintore,M.,et al, 2008
Mlutiple Sclerosis Risk After Optic Neuritis: Final Optic Neuritis Treatment Trial Follow-Up
Arch Neurol 65:727-732, The Optic Neuritis Study Group, 2008
Effect of Early Verus Delayed Interferon Beta-1b Treatment on Disability After a First Clinical Event Suggestive of Multiple Sclerosis: A 3-Year Follow-Up Analysis of the BENEFIT Study
Lancet 370:389-397, Kappos,L.,et al, 2007
Mangnetic Resonance Imaging Effects of Interferon Beta-1b in the BENEFIT Study: Integrated 2-Year Results
Arch Neurol 64:1292-1298, Barkhof,F.,et al, 2007
Clinically Isolated Syndromes, A New Oligoclonal Band Test Accurately Predicts Conversion to MS
Neurol 66:576-578, Masjuan,J.,et al, 2006
IM Interferon B-1a Delays Definite Multiple Sclerosis 5 Years After a First Demyelinating Event
Neurol 66:678-684, CHAMPIONS Study Group, 2006
Most Patients With Multiple Sclerosis or a Clinically Isolated Demyelinating Syndrome Should be Treated at the Time of Diagnosis
Arch Neurol 63:614-619, Frohman,E.M.,et al, 2006